首页 > 最新文献

癌症耐药(英文)最新文献

英文 中文
New insights for drug resistance in metastatic castration-resistant prostate cancer. 转移性抗性前列腺癌耐药性的新见解。
IF 4.6 Q1 ONCOLOGY Pub Date : 2022-08-02 eCollection Date: 2022-01-01 DOI: 10.20517/cdr.2022.83
Prem Prakash Kushwaha, Sanjay Gupta

Prostate cancer is the most common cancer and is the second leading cause of cancer-related deaths among men in the United States. Androgen deprivation therapy (ADT) is the standard treatment for advanced-stage prostate cancer; however, this treatment eventually fails, leading to an incurable disease subtype known as metastatic castration-resistant prostate cancer (mCRPC). There are several molecular mechanisms that facilitate the development of mCRPC engaging androgen receptor (AR) growth axis, including AR amplification, gain of function AR mutations, and AR splice variants that are constitutively active and are a foremost factor for mCRPC development. AR-independent mechanisms with exceptionally low or absent AR expression found in cancer cells suppress ADT effectiveness and contribute to aggressive variants, including neuroendocrine differentiation. Several other AR regulatory factors such as epigenetic modification(s), and DNA damage response have been reported during post-ADT exposure and play a crucial role in mCRPC development. Therefore, targeting prostate cancer cells before their progression to mCRPC would improve patient outcomes. This special issue in "Cancer Drug Resistance" focuses on understanding the mechanism(s) and development of mCRPC resistance. This special issue also highlights the therapeutic strategies to combat against resistant subtype. This issue comprehensively reviews the mCRPC and delivers the update in the forum of mCRPC resistance development.

前列腺癌是最常见的癌症,也是美国男性癌症相关死亡的第二大原因。雄激素剥夺疗法(ADT)是晚期前列腺癌的标准治疗方法;然而,这种治疗方法最终会失败,导致一种无法治愈的疾病亚型,即转移性抗性前列腺癌(mCRPC)。有几种分子机制可促进雄激素受体(AR)生长轴参与 mCRPC 的发展,其中包括 AR 扩增、AR 功能增益突变以及构成性活跃的 AR 剪接变体,它们是 mCRPC 发展的首要因素。在癌细胞中发现的 AR 表达异常低或缺失的 AR 依赖性机制会抑制 ADT 的有效性,并导致侵袭性变异,包括神经内分泌分化。有报告称,在ADT暴露后,其他一些AR调控因素(如表观遗传修饰和DNA损伤反应)在mCRPC的发展中起着至关重要的作用。因此,在前列腺癌细胞发展为 mCRPC 之前对其进行靶向治疗将改善患者的预后。本期 "癌症耐药性 "特刊的重点是了解mCRPC耐药性的机制和发展。本特刊还重点介绍了对抗耐药亚型的治疗策略。本期特刊全面回顾了mCRPC,并在mCRPC耐药性发展论坛上介绍了最新进展。
{"title":"New insights for drug resistance in metastatic castration-resistant prostate cancer.","authors":"Prem Prakash Kushwaha, Sanjay Gupta","doi":"10.20517/cdr.2022.83","DOIUrl":"10.20517/cdr.2022.83","url":null,"abstract":"<p><p>Prostate cancer is the most common cancer and is the second leading cause of cancer-related deaths among men in the United States. Androgen deprivation therapy (ADT) is the standard treatment for advanced-stage prostate cancer; however, this treatment eventually fails, leading to an incurable disease subtype known as metastatic castration-resistant prostate cancer (mCRPC). There are several molecular mechanisms that facilitate the development of mCRPC engaging androgen receptor (AR) growth axis, including AR amplification, gain of function AR mutations, and AR splice variants that are constitutively active and are a foremost factor for mCRPC development. AR-independent mechanisms with exceptionally low or absent AR expression found in cancer cells suppress ADT effectiveness and contribute to aggressive variants, including neuroendocrine differentiation. Several other AR regulatory factors such as epigenetic modification(s), and DNA damage response have been reported during post-ADT exposure and play a crucial role in mCRPC development. Therefore, targeting prostate cancer cells before their progression to mCRPC would improve patient outcomes. This special issue in \"Cancer Drug Resistance\" focuses on understanding the mechanism(s) and development of mCRPC resistance. This special issue also highlights the therapeutic strategies to combat against resistant subtype. This issue comprehensively reviews the mCRPC and delivers the update in the forum of mCRPC resistance development.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2022-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A nano-enhanced vaccine for metastatic melanoma immunotherapy. 用于转移性黑色素瘤免疫治疗的纳米增强疫苗。
Pub Date : 2022-07-07 eCollection Date: 2022-01-01 DOI: 10.20517/cdr.2021.132
Katelyn E Salotto, Walter C Olson, Karlyn E Pollack, Anuradha Illendula, Elishama Michel, Sydney Henriques, Todd Fox, Susan Walker, Marya Dunlap-Brown, Craig L Slingluff, Mark Kester, Helena W Snyder

Aim: Despite the huge advancements in cancer therapies and treatments over the past decade, most patients with metastasized melanoma still die from the disease. This poor prognosis largely results from resistance to conventional chemotherapies and other cytotoxic drugs. We have previously identified 6 antigenic peptides derived from melanomas that have proven efficacious for activating CD4+ T cells in clinical trials for melanoma. Our aim was to improve pharmacodynamics, pharmacokinetic and toxicological parameters by individually encapsulating each of the 6 melanoma helper peptides within their own immunogenic nanoliposomes. Methods: We modified these liposomes as necessary to account for differences in the peptides' chemical properties, resulting in 3 distinct formulations. To further enhance immunogenicity, we also incorporated KDO2, a TLR4 agonist, into the lipid bilayer of all nanoliposome formulations. We then conducted in vivo imaging studies in mice and ex vivo cell studies from 2 patient samples who both strongly expressed one of the identified peptides. Results: We demonstrate that these liposomes, loaded with the different melanoma helper peptides, can be readily mixed together and simultaneously delivered without toxicity in vivo. These liposomes are capable of being diffused to the secondary lymphoid organs very quickly and for at least 6 days. In addition, we show that these immunogenic liposomes enhance immune responses to specific peptides ex vivo. Conclusion: Lipid-based delivery systems, including nanoliposomes and lipid nanoparticles, have now been validated for pharmacological (small molecules, bioactive lipids) and molecular (mRNA, siRNA) therapeutic approaches. However, the utility of these formulations as cancer vaccines, delivering antigenic peptides, has not yet achieved the same degree of commercial success. Here, we describe the novel and successful development of a nanoliposome-based cancer vaccine for melanoma. These vaccines help to circumvent drug resistance by increasing a patient's T cell response, making them more susceptible to checkpoint blockade therapy.

目的:尽管在过去的十年里,癌症治疗和治疗取得了巨大的进步,但大多数转移性黑色素瘤患者仍然死于这种疾病。这种不良预后主要是由于对常规化疗和其他细胞毒性药物的耐药性。我们之前已经确定了6种来源于黑色素瘤的抗原肽,这些抗原肽在黑色素瘤的临床试验中被证明对激活CD4+ T细胞有效。我们的目的是通过将6种黑色素瘤辅助肽单独封装在其自身的免疫原性纳米脂质体中来改善药效学、药代动力学和毒理学参数。方法:我们对这些脂质体进行了必要的修饰,以解释肽化学性质的差异,从而得到3种不同的配方。为了进一步增强免疫原性,我们还将TLR4激动剂KDO2加入到所有纳米脂质体制剂的脂质双分子层中。然后,我们对小鼠进行了体内成像研究,并对2例患者样本进行了体外细胞研究,他们都强烈表达了所鉴定的肽之一。结果:我们证明了这些脂质体,装载了不同的黑色素瘤辅助肽,可以很容易地混合在一起,同时在体内无毒递送。这些脂质体能够迅速扩散到次级淋巴器官,至少持续6天。此外,我们发现这些免疫原性脂质体增强了对体内特定肽的免疫反应。结论:基于脂质的递送系统,包括纳米脂质体和脂质纳米颗粒,现已被证实可用于药理学(小分子,生物活性脂质)和分子(mRNA, siRNA)治疗方法。然而,这些配方作为癌症疫苗的效用,提供抗原肽,尚未取得同样程度的商业成功。在这里,我们描述了一种基于纳米脂质体的黑色素瘤癌症疫苗的新颖和成功的发展。这些疫苗通过增加患者的T细胞反应来帮助规避耐药性,使他们更容易受到检查点封锁疗法的影响。
{"title":"A nano-enhanced vaccine for metastatic melanoma immunotherapy.","authors":"Katelyn E Salotto,&nbsp;Walter C Olson,&nbsp;Karlyn E Pollack,&nbsp;Anuradha Illendula,&nbsp;Elishama Michel,&nbsp;Sydney Henriques,&nbsp;Todd Fox,&nbsp;Susan Walker,&nbsp;Marya Dunlap-Brown,&nbsp;Craig L Slingluff,&nbsp;Mark Kester,&nbsp;Helena W Snyder","doi":"10.20517/cdr.2021.132","DOIUrl":"https://doi.org/10.20517/cdr.2021.132","url":null,"abstract":"<p><p><b>Aim</b>: Despite the huge advancements in cancer therapies and treatments over the past decade, most patients with metastasized melanoma still die from the disease. This poor prognosis largely results from resistance to conventional chemotherapies and other cytotoxic drugs. We have previously identified 6 antigenic peptides derived from melanomas that have proven efficacious for activating CD4<sup>+</sup> T cells in clinical trials for melanoma. Our aim was to improve pharmacodynamics, pharmacokinetic and toxicological parameters by individually encapsulating each of the 6 melanoma helper peptides within their own immunogenic nanoliposomes. <b>Methods</b>: We modified these liposomes as necessary to account for differences in the peptides' chemical properties, resulting in 3 distinct formulations. To further enhance immunogenicity, we also incorporated KDO2, a TLR4 agonist, into the lipid bilayer of all nanoliposome formulations. We then conducted <i>in vivo</i> imaging studies in mice and <i>ex vivo</i> cell studies from 2 patient samples who both strongly expressed one of the identified peptides. <b>Results</b>: We demonstrate that these liposomes, loaded with the different melanoma helper peptides, can be readily mixed together and simultaneously delivered without toxicity <i>in vivo</i>. These liposomes are capable of being diffused to the secondary lymphoid organs very quickly and for at least 6 days. In addition, we show that these immunogenic liposomes enhance immune responses to specific peptides <i>ex vivo</i>. <b>Conclusion</b>: Lipid-based delivery systems, including nanoliposomes and lipid nanoparticles, have now been validated for pharmacological (small molecules, bioactive lipids) and molecular (mRNA, siRNA) therapeutic approaches. However, the utility of these formulations as cancer vaccines, delivering antigenic peptides, has not yet achieved the same degree of commercial success. Here, we describe the novel and successful development of a nanoliposome-based cancer vaccine for melanoma. These vaccines help to circumvent drug resistance by increasing a patient's T cell response, making them more susceptible to checkpoint blockade therapy.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40385714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells. 丁素诱导的mir -186-5p依赖性TWIST1调控影响恶性胸膜间皮瘤细胞对顺铂的耐药性和生物能量学。
Pub Date : 2022-07-03 eCollection Date: 2022-01-01 DOI: 10.20517/cdr.2022.56
Mario Cioce, Daniela Rutigliano, Annamaria Puglielli, Vito Michele Fazio

Aim: Malignant pleural mesothelioma is a chemoresistant tumor, and biphasic and sarcomatoid histologies portend the worst prognosis for malignant pleural mesothelioma (MPM) patients. We obtained the microRNA expression profile of three biphasic-sarcomatoid MPM cell lines to identify commonly expressed microRNAs and evaluate the effect of butein, a chemo-sensitizing compound, on this microRNA subset. Methods: Nanostring-based microRNA profiling and analysis through the ROSALIND platform were employed to identify the commonly modulated microRNAs and their targets. MicroRNA-mimic transfection, Luciferase assay, and Western blotting were employed to show specific perturbation of TWIST1 levels by miR-186-5p. Sphere-forming assays, invasion assay, and metabolic profiling were used to assess the biological consequences of the butein-instigated miR-186-5p-mediated perturbation of TWIST1 levels. TGCA analysis was used to search for the correlation between TWIST1 and miR-186-5p levels in biphasic and epithelioid MPM specimens. Results: We identified a set of perturbed microRNAs, common to three biphasic/sarcomatoid MPM cell lines, after butein treatment. When focusing on miR-186-5p, we unraveled a butein-ignited and miR-186-5p-mediated modulation of TWIST1 levels which affected the 3D anchorage-independent growth, cisplatin resistance, invasion, and bioenergetics of the MPM cell lines tested. We showed that miR-186-5p and TWIST1 levels are anti-correlated in biphasic MPM specimens from TCGA. Conclusion: We unraveled a novel mechanism of action of butein, which attenuated the pro-tumorigenic features of MPM at least through a miR-186-5p-TWIST1 axis. We suggest that those activities converge into the chemo-sensitizing effect of this compound and may be of translational relevance.

目的:恶性胸膜间皮瘤是一种化疗耐药的肿瘤,双相和肉瘤样组织学预示着恶性胸膜间皮瘤(MPM)患者预后最差。我们获得了三种双相肉瘤样MPM细胞系的microRNA表达谱,以鉴定常见表达的microRNA,并评估蛋白(一种化学增敏化合物)对该microRNA亚群的影响。方法:采用基于纳米链的microRNA谱分析和ROSALIND平台分析,鉴定常见的microRNA及其靶标。采用microrna模拟转染、荧光素酶测定和Western blotting来显示miR-186-5p对TWIST1水平的特异性扰动。球体形成试验、侵袭试验和代谢分析被用来评估蛋白诱导的mir -186-5p介导的TWIST1水平扰动的生物学后果。TGCA分析用于寻找双相和上皮样MPM标本中TWIST1与miR-186-5p水平的相关性。结果:在蛋白处理后,我们发现了一组在三种双相/肉瘤样MPM细胞系中常见的受干扰的microrna。当关注miR-186-5p时,我们揭示了蛋白点燃和miR-186-5p介导的TWIST1水平的调节,这影响了所测试的MPM细胞系的3D非锚定生长、顺铂抗性、侵袭和生物能量学。我们发现,在TCGA的双相MPM标本中,miR-186-5p和TWIST1水平是反相关的。结论:我们揭示了一种新的蛋白作用机制,它至少通过miR-186-5p-TWIST1轴减弱了MPM的致瘤性特征。我们认为,这些活性会聚为该化合物的化学致敏作用,可能具有翻译相关性。
{"title":"Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells.","authors":"Mario Cioce,&nbsp;Daniela Rutigliano,&nbsp;Annamaria Puglielli,&nbsp;Vito Michele Fazio","doi":"10.20517/cdr.2022.56","DOIUrl":"https://doi.org/10.20517/cdr.2022.56","url":null,"abstract":"<p><p><b>Aim:</b> Malignant pleural mesothelioma is a chemoresistant tumor, and biphasic and sarcomatoid histologies portend the worst prognosis for malignant pleural mesothelioma (MPM) patients. We obtained the microRNA expression profile of three biphasic-sarcomatoid MPM cell lines to identify commonly expressed microRNAs and evaluate the effect of butein, a chemo-sensitizing compound, on this microRNA subset. <b>Methods:</b> Nanostring-based microRNA profiling and analysis through the ROSALIND platform were employed to identify the commonly modulated microRNAs and their targets. MicroRNA-mimic transfection, Luciferase assay, and Western blotting were employed to show specific perturbation of TWIST1 levels by miR-186-5p. Sphere-forming assays, invasion assay, and metabolic profiling were used to assess the biological consequences of the butein-instigated miR-186-5p-mediated perturbation of TWIST1 levels. TGCA analysis was used to search for the correlation between TWIST1 and miR-186-5p levels in biphasic and epithelioid MPM specimens. <b>Results:</b> We identified a set of perturbed microRNAs, common to three biphasic/sarcomatoid MPM cell lines, after butein treatment. When focusing on miR-186-5p, we unraveled a butein-ignited and miR-186-5p-mediated modulation of TWIST1 levels which affected the 3D anchorage-independent growth, cisplatin resistance, invasion, and bioenergetics of the MPM cell lines tested. We showed that miR-186-5p and TWIST1 levels are anti-correlated in biphasic MPM specimens from TCGA. <b>Conclusion:</b> We unraveled a novel mechanism of action of butein, which attenuated the pro-tumorigenic features of MPM at least through a miR-186-5p-TWIST1 axis. We suggest that those activities converge into the chemo-sensitizing effect of this compound and may be of translational relevance.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Insight into the molecular mechanisms of gastric cancer stem cell in drug resistance of gastric cancer. 胃癌干细胞在胃癌耐药中的分子机制研究。
Pub Date : 2022-07-01 eCollection Date: 2022-01-01 DOI: 10.20517/cdr.2022.11
Jixian Xiong, Tiantian Zhang, Penglin Lan, Shuhong Zhang, Li Fu

Gastric cancer (GC) is one of the most common causes of cancer-related death worldwide, and gastric cancer stem cells (GCSCs) are considered as the major factor for resistance to conventional radio- and chemotherapy. Accumulating evidence in recent years implies that GCSCs regulate the drug resistance in GC through multiple mechanisms, including dormancy, drug trafficking, drug metabolism and targeting, apoptosis, DNA damage, epithelial-mesenchymal transition, and tumor microenvironment. In this review, we summarize current advancements regarding the relationship between GCSCs and drug resistance and evaluate the molecular bases of GCSCs in drug resistance.

胃癌(GC)是世界范围内最常见的癌症相关死亡原因之一,胃癌干细胞(GCSCs)被认为是导致常规放化疗耐药的主要因素。近年来越来越多的证据表明,GCSCs通过休眠、药物转运、药物代谢和靶向、细胞凋亡、DNA损伤、上皮-间质转化、肿瘤微环境等多种机制调控胃癌耐药。本文综述了GCSCs与耐药关系的研究进展,并对GCSCs在耐药中的分子基础进行了评价。
{"title":"Insight into the molecular mechanisms of gastric cancer stem cell in drug resistance of gastric cancer.","authors":"Jixian Xiong,&nbsp;Tiantian Zhang,&nbsp;Penglin Lan,&nbsp;Shuhong Zhang,&nbsp;Li Fu","doi":"10.20517/cdr.2022.11","DOIUrl":"https://doi.org/10.20517/cdr.2022.11","url":null,"abstract":"<p><p>Gastric cancer (GC) is one of the most common causes of cancer-related death worldwide, and gastric cancer stem cells (GCSCs) are considered as the major factor for resistance to conventional radio- and chemotherapy. Accumulating evidence in recent years implies that GCSCs regulate the drug resistance in GC through multiple mechanisms, including dormancy, drug trafficking, drug metabolism and targeting, apoptosis, DNA damage, epithelial-mesenchymal transition, and tumor microenvironment. In this review, we summarize current advancements regarding the relationship between GCSCs and drug resistance and evaluate the molecular bases of GCSCs in drug resistance.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40385715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Microvesicles: the functional mediators in sorafenib resistance. 微泡:索拉非尼耐药的功能介质。
Pub Date : 2022-06-23 eCollection Date: 2022-01-01 DOI: 10.20517/cdr.2021.137
Cong He, Doulathunnisa Jaffar Ali, Bo Sun, Bei-Cheng Sun, Zhong-Dang Xiao
Overcoming drug resistance in cancer therapies remains challenging, and the tumor microenvironment plays an important part in it. Microvesicles (MVs) are functional natural carriers of cellular information, participate in intercellular communication, and dynamically regulate the tumor microenvironment. They contribute to drug resistance by transferring functional molecules between cells. Conversely, due to their specific cell or tissue targeting ability, MVs are considered as carriers for therapeutic molecules to reverse drug resistance. Thus, in this mini-review, we aim to highlight the crucial role of MVs in cell-to-cell communication and therefore their diverse impact mainly on liver cancer progression and treatment. In addition, we summarize the possible mechanisms for sorafenib resistance (one of the main hurdles in hepatocellular carcinoma treatments) and recent advances in using MVs to reverse sorafenib resistance in liver cancer therapies. Identifying the functional role of MVs in cancer therapy might provide a new aspect for developing precise novel therapeutics in the future.
克服癌症治疗中的耐药性仍然具有挑战性,肿瘤微环境在其中起着重要作用。微囊泡(Microvesicles, mv)是细胞信息的天然载体,参与细胞间通讯,动态调节肿瘤微环境。它们通过在细胞之间转移功能分子来促进耐药性。相反,由于其特定的细胞或组织靶向能力,mv被认为是治疗分子逆转耐药性的载体。因此,在这篇综述中,我们的目标是强调mv在细胞间通讯中的关键作用,因此它们主要对肝癌的进展和治疗有不同的影响。此外,我们总结了索拉非尼耐药(肝细胞癌治疗的主要障碍之一)的可能机制,以及在肝癌治疗中使用mv逆转索拉非尼耐药的最新进展。确定mv在癌症治疗中的功能作用可能为未来开发精确的新疗法提供新的方面。
{"title":"Microvesicles: the functional mediators in sorafenib resistance.","authors":"Cong He,&nbsp;Doulathunnisa Jaffar Ali,&nbsp;Bo Sun,&nbsp;Bei-Cheng Sun,&nbsp;Zhong-Dang Xiao","doi":"10.20517/cdr.2021.137","DOIUrl":"https://doi.org/10.20517/cdr.2021.137","url":null,"abstract":"Overcoming drug resistance in cancer therapies remains challenging, and the tumor microenvironment plays an important part in it. Microvesicles (MVs) are functional natural carriers of cellular information, participate in intercellular communication, and dynamically regulate the tumor microenvironment. They contribute to drug resistance by transferring functional molecules between cells. Conversely, due to their specific cell or tissue targeting ability, MVs are considered as carriers for therapeutic molecules to reverse drug resistance. Thus, in this mini-review, we aim to highlight the crucial role of MVs in cell-to-cell communication and therefore their diverse impact mainly on liver cancer progression and treatment. In addition, we summarize the possible mechanisms for sorafenib resistance (one of the main hurdles in hepatocellular carcinoma treatments) and recent advances in using MVs to reverse sorafenib resistance in liver cancer therapies. Identifying the functional role of MVs in cancer therapy might provide a new aspect for developing precise novel therapeutics in the future.","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40385713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
An overview of resistance to chemotherapy in osteosarcoma and future perspectives. 骨肉瘤化疗耐药的综述及未来展望。
Pub Date : 2022-06-23 eCollection Date: 2022-01-01 DOI: 10.20517/cdr.2022.18
Dorian Yarih Garcia-Ortega, Sara Aileen Cabrera-Nieto, Haydee Sarai Caro-Sánchez, Marlid Cruz-Ramos

Osteosarcoma (OS) is the most common type of bone sarcoma. Despite the availability of multimodal treatment with surgery and chemotherapy, the clinical results remain unsatisfactory. The main reason for the poor outcomes in patients with OS is the development of resistance to methotrexate, cisplatin, doxorubicin, and ifosfamide. Molecular and cellular mechanisms associated with resistance to chemotherapy include DNA repair and cell-cycle alterations, enhanced drug efflux, increased detoxification, resistance to apoptosis, autophagy, tumor extracellular matrix, and angiogenesis. This versatility of cells to generate chemoresistance has motivated the use of anti-angiogenic therapy based on tyrosine kinase inhibitors. This approach has shown that other therapies, along with standard chemotherapy, can improve responses to therapy in patients with OS. Moreover, microRNAs may act as predictors of drug resistance in OS. This review provides insight into the molecular and cellular mechanisms involved in the development of resistance during the treatment of OS and discusses promising novel therapies (e.g., afatinib and palbociclib) for overcoming resistance to chemotherapy in OS.

骨肉瘤(OS)是最常见的骨肉瘤类型。尽管有手术和化疗的多模式治疗,临床结果仍然令人不满意。OS患者预后不良的主要原因是对甲氨蝶呤、顺铂、阿霉素和异环磷酰胺产生耐药性。与化疗耐药相关的分子和细胞机制包括DNA修复和细胞周期改变、药物外排增强、解毒增强、对凋亡、自噬、肿瘤细胞外基质和血管生成的抵抗。细胞产生化疗耐药的多功能性促使了基于酪氨酸激酶抑制剂的抗血管生成治疗的使用。这种方法表明,其他疗法,以及标准化疗,可以改善OS患者的治疗反应。此外,microrna可能作为OS耐药的预测因子。本文综述了在OS治疗过程中涉及耐药性发展的分子和细胞机制,并讨论了有前途的新疗法(例如,阿法替尼和帕博西尼)来克服OS化疗耐药性。
{"title":"An overview of resistance to chemotherapy in osteosarcoma and future perspectives.","authors":"Dorian Yarih Garcia-Ortega,&nbsp;Sara Aileen Cabrera-Nieto,&nbsp;Haydee Sarai Caro-Sánchez,&nbsp;Marlid Cruz-Ramos","doi":"10.20517/cdr.2022.18","DOIUrl":"https://doi.org/10.20517/cdr.2022.18","url":null,"abstract":"<p><p>Osteosarcoma (OS) is the most common type of bone sarcoma. Despite the availability of multimodal treatment with surgery and chemotherapy, the clinical results remain unsatisfactory. The main reason for the poor outcomes in patients with OS is the development of resistance to methotrexate, cisplatin, doxorubicin, and ifosfamide. Molecular and cellular mechanisms associated with resistance to chemotherapy include DNA repair and cell-cycle alterations, enhanced drug efflux, increased detoxification, resistance to apoptosis, autophagy, tumor extracellular matrix, and angiogenesis. This versatility of cells to generate chemoresistance has motivated the use of anti-angiogenic therapy based on tyrosine kinase inhibitors. This approach has shown that other therapies, along with standard chemotherapy, can improve responses to therapy in patients with OS. Moreover, microRNAs may act as predictors of drug resistance in OS. This review provides insight into the molecular and cellular mechanisms involved in the development of resistance during the treatment of OS and discusses promising novel therapies (e.g., afatinib and palbociclib) for overcoming resistance to chemotherapy in OS.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Base excision repair accessory factors in senescence avoidance and resistance to treatments. 基底切除修复辅助因子在避免衰老和抵抗治疗中的作用。
Pub Date : 2022-06-22 eCollection Date: 2022-01-01 DOI: 10.20517/cdr.2022.36
Elise Vickridge, Camila C F Faraco, Alain Nepveu

Cancer cells, in which the RAS and PI3K pathways are activated, produce high levels of reactive oxygen species (ROS), which cause oxidative DNA damage and ultimately cellular senescence. This process has been documented in tissue culture, mouse models, and human pre-cancerous lesions. In this context, cellular senescence functions as a tumour suppressor mechanism. Some rare cancer cells, however, manage to adapt to avoid senescence and continue to proliferate. One well-documented mode of adaptation involves increased production of antioxidants often associated with inactivation of the KEAP1 tumour suppressor gene and the resulting upregulation of the NRF2 transcription factor. In this review, we detail an alternative mode of adaptation to oxidative DNA damage induced by ROS: the increased activity of the base excision repair (BER) pathway, achieved through the enhanced expression of BER enzymes and DNA repair accessory factors. These proteins, exemplified here by the CUT domain proteins CUX1, CUX2, and SATB1, stimulate the activity of BER enzymes. The ensued accelerated repair of oxidative DNA damage enables cancer cells to avoid senescence despite high ROS levels. As a by-product of this adaptation, these cancer cells exhibit increased resistance to genotoxic treatments including ionizing radiation, temozolomide, and cisplatin. Moreover, considering the intrinsic error rate associated with DNA repair and translesion synthesis, the elevated number of oxidative DNA lesions caused by high ROS leads to the accumulation of mutations in the cancer cell population, thereby contributing to tumour heterogeneity and eventually to the acquisition of resistance, a major obstacle to clinical treatment.

在癌细胞中,RAS和PI3K通路被激活,产生高水平的活性氧(ROS),导致DNA氧化损伤,最终导致细胞衰老。这一过程已在组织培养、小鼠模型和人类癌前病变中得到证实。在这种情况下,细胞衰老作为肿瘤抑制机制发挥作用。然而,一些罕见的癌细胞设法适应以避免衰老并继续增殖。一种有充分证据的适应模式涉及抗氧化剂的产生增加,通常与KEAP1肿瘤抑制基因失活和NRF2转录因子的上调有关。在这篇综述中,我们详细介绍了ROS诱导的DNA氧化损伤的另一种适应模式:碱基切除修复(BER)途径活性的增加,通过增强BER酶和DNA修复辅助因子的表达来实现。这些蛋白,例如CUT结构域蛋白CUX1, CUX2和SATB1,刺激BER酶的活性。随之而来的DNA氧化损伤的加速修复使癌细胞在高ROS水平下避免衰老。作为这种适应的副产品,这些癌细胞对包括电离辐射、替莫唑胺和顺铂在内的基因毒性治疗表现出更强的耐药性。此外,考虑到与DNA修复和翻译合成相关的固有错误率,高ROS引起的氧化DNA损伤数量增加导致癌细胞群中突变的积累,从而导致肿瘤异质性,最终获得耐药性,这是临床治疗的主要障碍。
{"title":"Base excision repair accessory factors in senescence avoidance and resistance to treatments.","authors":"Elise Vickridge,&nbsp;Camila C F Faraco,&nbsp;Alain Nepveu","doi":"10.20517/cdr.2022.36","DOIUrl":"https://doi.org/10.20517/cdr.2022.36","url":null,"abstract":"<p><p>Cancer cells, in which the RAS and PI3K pathways are activated, produce high levels of reactive oxygen species (ROS), which cause oxidative DNA damage and ultimately cellular senescence. This process has been documented in tissue culture, mouse models, and human pre-cancerous lesions. In this context, cellular senescence functions as a tumour suppressor mechanism. Some rare cancer cells, however, manage to adapt to avoid senescence and continue to proliferate. One well-documented mode of adaptation involves increased production of antioxidants often associated with inactivation of the <i>KEAP1</i> tumour suppressor gene and the resulting upregulation of the NRF2 transcription factor. In this review, we detail an alternative mode of adaptation to oxidative DNA damage induced by ROS: the increased activity of the base excision repair (BER) pathway, achieved through the enhanced expression of BER enzymes and DNA repair accessory factors. These proteins, exemplified here by the CUT domain proteins CUX1, CUX2, and SATB1, stimulate the activity of BER enzymes. The ensued accelerated repair of oxidative DNA damage enables cancer cells to avoid senescence despite high ROS levels. As a by-product of this adaptation, these cancer cells exhibit increased resistance to genotoxic treatments including ionizing radiation, temozolomide, and cisplatin. Moreover, considering the intrinsic error rate associated with DNA repair and translesion synthesis, the elevated number of oxidative DNA lesions caused by high ROS leads to the accumulation of mutations in the cancer cell population, thereby contributing to tumour heterogeneity and eventually to the acquisition of resistance, a major obstacle to clinical treatment.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40385161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Therapeutics to harness the immune microenvironment in multiple myeloma. 利用免疫微环境治疗多发性骨髓瘤。
Pub Date : 2022-06-22 eCollection Date: 2022-01-01 DOI: 10.20517/cdr.2022.23
James J Ignatz-Hoover, James J Driscoll

Multiple myeloma (MM) remains an incurable, genetically heterogeneous disease characterized by the uncontrolled proliferation of transformed plasma cells nurtured within a permissive bone marrow (BM) microenvironment. Current therapies leverage the unique biology of MM cells and target the immune microenvironment that drives tumor growth and facilitates immune evasion. Proteasome inhibitors and immunomodulatory drugs were initially introduced to complement and have now supplanted cytotoxic chemotherapy as frontline anti-myeloma agents. Recently, monoclonal antibodies, bispecific antibodies, and chimeric antigen receptor T cells were developed to revamp the immune system to overcome immune suppression and improve patient responses. While current MM therapies have markedly extended patient survival, acquired drug resistance inevitably emerges and drives disease progression. The logical progression for the next generation of MM therapies would be to design and validate agents that prevent and/or overcome acquired resistance to immunotherapies. The complex BM microenvironment promotes resistance to both current anti-myeloma agents and emerging immunotherapies. Myeloma cells are intertwined with a complex BM immune microenvironment that contributes to the development of adaptive drug resistance. Here, we describe recently FDA-approved and investigational anti-myeloma agents that directly or indirectly target the BM microenvironment to prevent or overcome drug resistance. Synergistic effects of anti-myeloma agents may foster the development of rationally-designed drug cocktails that prevent BM-mediated resistance to immunotherapies.

多发性骨髓瘤(MM)仍然是一种无法治愈的遗传异质性疾病,其特征是在允许的骨髓(BM)微环境中培养的转化浆细胞不受控制的增殖。目前的治疗方法利用MM细胞独特的生物学特性,并针对驱动肿瘤生长和促进免疫逃避的免疫微环境。蛋白酶体抑制剂和免疫调节药物最初用于补充,现在已取代细胞毒性化疗作为一线抗骨髓瘤药物。最近,单克隆抗体、双特异性抗体和嵌合抗原受体T细胞被开发出来,以改造免疫系统,克服免疫抑制,改善患者的反应。虽然目前的MM治疗显着延长了患者的生存期,但获得性耐药不可避免地出现并推动疾病进展。下一代MM治疗的逻辑进展将是设计和验证预防和/或克服免疫治疗获得性耐药的药物。复杂的骨髓微环境促进了对当前抗骨髓瘤药物和新兴免疫疗法的耐药性。骨髓瘤细胞与复杂的骨髓免疫微环境交织在一起,有助于适应性耐药的发展。在这里,我们描述了最近fda批准的和正在研究的抗骨髓瘤药物,这些药物直接或间接地靶向骨髓微环境来预防或克服耐药性。抗骨髓瘤药物的协同作用可能促进合理设计的药物鸡尾酒的发展,以防止脑脊髓瘤介导的免疫疗法耐药。
{"title":"Therapeutics to harness the immune microenvironment in multiple myeloma.","authors":"James J Ignatz-Hoover,&nbsp;James J Driscoll","doi":"10.20517/cdr.2022.23","DOIUrl":"https://doi.org/10.20517/cdr.2022.23","url":null,"abstract":"<p><p>Multiple myeloma (MM) remains an incurable, genetically heterogeneous disease characterized by the uncontrolled proliferation of transformed plasma cells nurtured within a permissive bone marrow (BM) microenvironment. Current therapies leverage the unique biology of MM cells and target the immune microenvironment that drives tumor growth and facilitates immune evasion. Proteasome inhibitors and immunomodulatory drugs were initially introduced to complement and have now supplanted cytotoxic chemotherapy as frontline anti-myeloma agents. Recently, monoclonal antibodies, bispecific antibodies, and chimeric antigen receptor T cells were developed to revamp the immune system to overcome immune suppression and improve patient responses. While current MM therapies have markedly extended patient survival, acquired drug resistance inevitably emerges and drives disease progression. The logical progression for the next generation of MM therapies would be to design and validate agents that prevent and/or overcome acquired resistance to immunotherapies. The complex BM microenvironment promotes resistance to both current anti-myeloma agents and emerging immunotherapies. Myeloma cells are intertwined with a complex BM immune microenvironment that contributes to the development of adaptive drug resistance. Here, we describe recently FDA-approved and investigational anti-myeloma agents that directly or indirectly target the BM microenvironment to prevent or overcome drug resistance. Synergistic effects of anti-myeloma agents may foster the development of rationally-designed drug cocktails that prevent BM-mediated resistance to immunotherapies.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40385712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report. PARPi单药治疗复发性高级别浆液性卵巢癌伴RAD51C体细胞突变1例
Pub Date : 2022-06-22 eCollection Date: 2022-01-01 DOI: 10.20517/cdr.2022.12
Siew-Fei Ngu, Hextan Y S Ngan, Karen K L Chan

We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation, treated with olaparib monotherapy. The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy, cytoreductive surgery, and postoperative chemotherapy. After a second cancer recurrence, she underwent FoundationOne CDx testing following disease progression on multiple lines of chemotherapy. Based on the FoundationOne CDx results, olaparib monotherapy was started. After 13 months of therapy, all lesions responded to the treatment, and she achieved complete response as demonstrated by normalization of the levels of CA125 and positron emission tomography-computed tomography (PET-CT). We plan to continue olaparib monotherapy until disease progression.

我们报告我们的经验,在管理复发卵巢癌患者与体细胞RAD51C突变,奥拉帕尼单药治疗。患者被诊断为4期高级别浆液性卵巢癌,并接受了新辅助化疗、细胞减缩手术和术后化疗。在第二次癌症复发后,她接受了FoundationOne CDx检测,并接受了多种化疗。基于FoundationOne CDx结果,开始奥拉帕尼单药治疗。经过13个月的治疗,所有病变都对治疗有反应,并且通过CA125和正电子发射断层扫描-计算机断层扫描(PET-CT)水平的正常化证明她达到了完全缓解。我们计划继续奥拉帕尼单药治疗直至疾病进展。
{"title":"A patient with relapsed high-grade serous ovarian carcinoma with somatic <i>RAD51C</i> mutations treated with PARPi monotherapy: a case report.","authors":"Siew-Fei Ngu,&nbsp;Hextan Y S Ngan,&nbsp;Karen K L Chan","doi":"10.20517/cdr.2022.12","DOIUrl":"https://doi.org/10.20517/cdr.2022.12","url":null,"abstract":"<p><p>We report our experience in the management of a relapsed ovarian cancer patient with somatic <i>RAD51C</i> mutation, treated with olaparib monotherapy. The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy, cytoreductive surgery, and postoperative chemotherapy. After a second cancer recurrence, she underwent FoundationOne CDx testing following disease progression on multiple lines of chemotherapy. Based on the FoundationOne CDx results, olaparib monotherapy was started. After 13 months of therapy, all lesions responded to the treatment, and she achieved complete response as demonstrated by normalization of the levels of CA125 and positron emission tomography-computed tomography (PET-CT). We plan to continue olaparib monotherapy until disease progression.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Ovarian cancer resistance to PARPi and platinum-containing chemotherapy. 卵巢癌对PARPi和含铂化疗的耐药性。
Pub Date : 2022-06-22 eCollection Date: 2022-01-01 DOI: 10.20517/cdr.2021.146
Rebekah Summey, Denise Uyar

Epithelial ovarian cancer remains the most lethal female malignancy despite options for systemic therapy and the emergence of targeted therapies. Although initial response to therapy is observed, recurrence and ultimately chemoresistance result in overall therapeutic failure. This pattern has been evident with platinum therapy since the 1980s. Significant excitement surrounded the approval of poly (ADP-ribose) polymerase inhibition (PARPi) as a novel therapeutic option, especially with the advent of personalized medicine, but resistance has similarly developed to these treatments. Novel agents are constantly being sought, but if the obstacle of chemoresistance remains, the durability of responses will remain tenuous. Unraveling the multifactorial mechanisms of platinum and PARPi resistance is increasingly important as a therapeutic failure with current strategies is almost assured. Focusing greater efforts on expanding the current understanding of the complex nature of platinum and PARPi chemoresistance has tremendous potential to improve clinical outcomes.

上皮性卵巢癌仍然是最致命的女性恶性肿瘤,尽管系统治疗的选择和靶向治疗的出现。虽然观察到对治疗的初始反应,但复发和最终的化疗耐药导致整体治疗失败。自20世纪80年代以来,这种模式在铂疗法中已经很明显。随着个性化医疗的出现,人们对聚(adp -核糖)聚合酶抑制(PARPi)作为一种新的治疗选择的批准感到非常兴奋,但对这些治疗的耐药性也同样出现了。人们不断寻找新的药物,但如果化学耐药性的障碍仍然存在,反应的持久性将仍然是脆弱的。揭示铂和PARPi耐药的多因素机制越来越重要,因为目前的治疗策略几乎肯定会失败。将更多的精力集中在扩大目前对铂和PARPi化疗耐药复杂性的理解上,对于改善临床结果具有巨大的潜力。
{"title":"Ovarian cancer resistance to PARPi and platinum-containing chemotherapy.","authors":"Rebekah Summey,&nbsp;Denise Uyar","doi":"10.20517/cdr.2021.146","DOIUrl":"https://doi.org/10.20517/cdr.2021.146","url":null,"abstract":"<p><p>Epithelial ovarian cancer remains the most lethal female malignancy despite options for systemic therapy and the emergence of targeted therapies. Although initial response to therapy is observed, recurrence and ultimately chemoresistance result in overall therapeutic failure. This pattern has been evident with platinum therapy since the 1980s. Significant excitement surrounded the approval of poly (ADP-ribose) polymerase inhibition (PARPi) as a novel therapeutic option, especially with the advent of personalized medicine, but resistance has similarly developed to these treatments. Novel agents are constantly being sought, but if the obstacle of chemoresistance remains, the durability of responses will remain tenuous. Unraveling the multifactorial mechanisms of platinum and PARPi resistance is increasingly important as a therapeutic failure with current strategies is almost assured. Focusing greater efforts on expanding the current understanding of the complex nature of platinum and PARPi chemoresistance has tremendous potential to improve clinical outcomes.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
癌症耐药(英文)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1